Recent Quotes (30 days)

You have no recent quotes
chg | %

Cascadian Therapeutics Inc (USA)  

(Public, NASDAQ:CASC)   Watch this stock  
Find more results for Nasdaq:ONTY
0.00 (0.00%)
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 3.49 - 10.98
Open     -
Vol / Avg. 0.00/160,262.00
Mkt cap 214.55M
P/E     -
Div/yield     -
EPS -2.85
Shares 49.24M
Beta 2.41
Inst. own 83%
May 11, 2017
Q1 2017 Cascadian Therapeutics Inc Earnings Release (Estimated)
May 9, 2017
Q1 2017 Cascadian Therapeutics Inc Earnings Call - Webcast
Mar 9, 2017
Q4 2016 Cascadian Therapeutics Inc Earnings Release
Mar 6, 2017
Cascadian Therapeutics Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -38.04% -64.17%
Return on average equity -43.95% -76.28%
Employees 57 -
CDP Score - -


2601 4th Ave Ste 500
SEATTLE, WA 98121-3222
United States - Map
+1-206-8012100 (Phone)
+1-206-8012101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Officers and directors

Christopher S. Henney Ph.D. Chairman of the Board
Age: 75
Bio & Compensation  - Reuters
Scott D. Myers President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Julia Marie Eastland Chief Financial Officer, Vice President - Corporate Development, Secretary
Age: 51
Bio & Compensation  - Reuters
Gary W. Christianson Chief Operating Officer
Age: 61
Bio & Compensation  - Reuters
Scott Peterson Ph.D. Chief Scientific Officer
Age: 54
Bio & Compensation  - Reuters
Robert W. Azelby Director
Age: 49
Bio & Compensation  - Reuters
Gwendolyn A. Fyfe M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Steven P. James Independent Director
Age: 57
Bio & Compensation  - Reuters
Ted W. Love M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Daniel Keith Spiegelman Independent Director
Age: 58
Bio & Compensation  - Reuters